Chardan Capital Maintains Buy on Alumis, Raises Price Target to $38

3/20/2026
Impact: 70
Healthcare

Chardan Capital analyst Janani Sundararajan has maintained a Buy rating on Alumis (NASDAQ: ALMS) and raised the price target from $37 to $38. This adjustment reflects a positive outlook for the company's performance in the market.

AI summary, not financial advice

Share: